HEALTH● LOWSep 8 · Sep 8, 2026, 12:03 PM
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
CNBC · global
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH51m agoThree Chili’s customers chemically burned after margarita mix-upThe Independent WorldHEALTH2h agoAmericans face higher costs and fewer options as Affordable Care Act open enrollment beginsThe Independent WorldHEALTH2h agoJohnson & Johnson reports lower mortality rates with Impella heart pumpsSeeking Alpha TechHEALTH3h agoNotable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focusSeeking Alpha Tech